Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Arcturus Therapeutics Holdings (ARCT) Leases (2019 - 2025)

Arcturus Therapeutics Holdings' Leases history spans 7 years, with the latest figure at $21.1 million for Q4 2025.

  • For Q4 2025, Leases fell 20.97% year-over-year to $21.1 million; the TTM value through Dec 2025 reached $21.1 million, down 20.97%, while the annual FY2025 figure was $21.1 million, 20.97% down from the prior year.
  • Leases reached $21.1 million in Q4 2025 per ARCT's latest filing, down from $23.8 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $34.5 million in Q2 2022 to a low of $5.2 million in Q1 2022.
  • Average Leases over 5 years is $22.9 million, with a median of $27.1 million recorded in 2024.
  • Peak YoY movement for Leases: fell 21.6% in 2022, then soared 501.66% in 2023.
  • A 5-year view of Leases shows it stood at $5.6 million in 2021, then soared by 479.3% to $32.5 million in 2022, then fell by 12.43% to $28.5 million in 2023, then dropped by 6.41% to $26.7 million in 2024, then decreased by 20.97% to $21.1 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Leases are $21.1 million (Q4 2025), $23.8 million (Q3 2025), and $24.8 million (Q2 2025).